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Rockall scoreAbstract Background: Upper gastrointestinal bleeding is usually classiﬁed as either variceal or
non-variceal. In cirrhotic patients, variceal bleeding has been extensively studied but, 30–40% of
cirrhotic patients who bleed have non-variceal upper gastrointestinal bleeding (NVUGIB) that is
frequently caused by gastro duodenal ulcers. Peptic ulcer bleeding (PUB) leads to substantial mor-
bidity and mortality in patients with liver cirrhosis.
Aim: The aim of this study was to assess the prevalence and outcome of PUB in patients with liver
cirrhosis.
Materials and methods: This was a cross-sectional study. Data on cirrhotic patients with PUB over
a seven-year period between January 2006 and January 2013 were collected.
Results: Among 103 patients with NVUGIB, 62 patients (60%) having PUB were assessed. Fifty
percent were male. Ages ranged from 37 to 72 years, mean 59 ± 7 years. The most common symp-
tom on presentation was hematemesis (53%). Hemodynamic instability on admission was found in
30 patients (48%). Eighteen patients (29%) had initial hemoglobin less than 7 g/dl. Twenty-seven
patients (44%) required blood transfusion and the average number of transfused blood units was
two. Forty patients (65%) bled from gastric ulcers. Eleven patients (18%) had ulcers with adherent
Table 1 Rockall numerical scoring
Initial score criteria
Age (years)
0 <60 years
1 60–79 years
2 >80 years
Shock
0 SBP* P100 mmHg & pul
(no shock)
1 SBP P100 mmHg & puls
(tachycardia)
2 SBP <100 mmHg (hypot
Comorbidity
0 Nil major
2 Cardiac failure, IHD** ot
3 Renal failure, liver failure
Additional criteria for full score
Diagnosis
0 Mallory–Weiss tear, no le
1 All other diagnoses
2 Malignancy of UGIb trac
Major stigmata of recent hemorrhage
0 None or dark spot only
2 Blood in UGI tract, adhe
spurting vessel
* Systolic blood pressure.
** Ischemic heart disease.
a Stigmata of recent bleeding.
b Upper gastrointestinal.
144 A. Gado et al.clot. Twenty-four percent of patients had a Rockall score more than ﬁve. Five patients (8%) rebled.
Complications were reported in seven patients (11%), mainly liver failure. Overall mortality was
8%. Male gender, adherent clot, bleeding recurrence, development of complications during admis-
sion and a Rockall score >5 were signiﬁcant factors for increasing mortality (P= 0.02, 0.016,
0.00001, 0.034 and 0.00003 respectively).
Conclusion: The commonest cause of NVUGIB in patients with liver cirrhosis was PUB. Mortality
in patients with PUB was particularly high among males, patients who had adherent clot, bleeding
recurrence, development of complications and a high Rockall score.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Upper gastrointestinal (UGI) bleeding is a common life threat-
ening condition in which mortality rates range from 4% to
15%.1 UGI bleeding is classiﬁed according to whether the
source of bleeding is variceal or non-variceal. In cirrhotic pa-
tients, variceal bleeding has been extensively studied. Nonethe-
less, 30–40% of cirrhotic patients who bleed have non-variceal
upper gastrointestinal bleeding (NVUGIB), and it is frequently
caused by gastro duodenal ulcers.1
The association of peptic ulcer and liver cirrhosis has been
extensively reported in the literature with an incidence varying
between 2% and 42%.2 The association of the two diseases is
recognized to be a serious problem. Cirrhotic patients with
peptic ulcer may be at an increased risk of bleeding due to
coagulation dysfunction and thrombocytopenia, conditions
that are frequently observed in these patients.3
Schistosomiasis and hepatitis C virus are common diseases
in Egypt with hepatitis C virus currently infecting 20.7% of thesystem.
se <100 beats per min.
e P100 beats per min.
ension)
her major comorbidity
, disseminated malignancy
sion identiﬁed and no SRBa
t
rent clot, visible orEgyptian population.4 Bolak Eldakror Hospital is a second-
ary-care governmental hospital in Giza, Egypt. The gastroin-
testinal endoscopy unit was set up in 1999. All patients
presenting with acute UGI bleeding have been assessed and
managed in house since 2004.5,6 A quality controlled disease
management protocol for acute bleeding was established with
the intention of improving the quality and efﬁciency of our
health care delivery. Clinical guidelines and a clinical care
pathway were developed within the availability of local thera-
peutic options in order to provide a stand-alone practical guide
for the team. Patients are classiﬁed as being at low or high risk
of rebleeding and mortality based on the Rockall risk score
(Table 1). Patients with a low risk of rebleeding and mortality
are discharged home and subsequently undergo diagnostic
endoscopy on the next available list. Those at high risk are
admitted to the hospital for intensive monitoring and early,
energetic resuscitation. Endoscopy is performed on the morn-
ing of the second day to establish the diagnosis, to control
bleeding and to prevent rebleeding if considered appropriate.
As with most government hospitals in Egypt balloon tampon-
ade, vasoactive drugs, IV proton pump inhibitor drugs, surgi-
cal shunts, trans-jugular intrahepatic porto-systemic shunts
and arterial embolization are not locally available.
The aim of this study was to assess the prevalence and out-
come of peptic ulcer bleeding (PUB) in patients with liver
cirrhosis.
2. Materials and methods
This was a cross-sectional, hospital based study performed in
cirrhotic patients with PUB over a 7-year period between
January 2006 and January 2013.
All patients presenting with acute UGI bleeding and a con-
ﬁrmed diagnosis of liver cirrhosis were admitted, assessed and
resuscitated in a three-bed intensive-care unit. Liver cirrhosis
was diagnosed on the basis of clinical and laboratory data
and ultrasonography. Histological examination of the liver
was not performed. The etiology of the liver disease was not
determined in all patients.
Those who were hemodynamically instable (heart rate
>100 beats/min, hypotension with a systolic pressure
<90 mmHg and/or diastolic value <60 mmHg) were man-
aged with crystalloid solutions with or without blood transfu-
sion. Patients with hemoglobin less than 7 g/dl were transfused
according to individual requirements. All patients received
prophylactic antibiotic therapy (IV third generation cephalo-
sporin) for suspected variceal bleeding. Endoscopy was per-
formed on the morning of the second day to establish the
diagnosis, to control bleeding and prevent rebleeding. All
Table 2 Patients with acute UGI bleeding and liver cirrhosis
who did not undergo endoscopy.
Causes Incidence (%)
Died rapidly on admission 45 (9%)
Unﬁt for endoscopy 35 (7%)
Speciﬁcally categorized as terminal care
patients
32 (6%)
Self-discharging prior to endoscopy being
undertaken
9 (2%)
Refused or whose family refused to consent
to endoscopy
7 (1%)
Speciﬁc contraindication to endoscopy 7 (1%)
Incomplete procedure due to agitated patient 5 (1%)
Unsuccessful esophageal intubation 2 (0.4%)
Total 142
Table 3 Endoscopic ﬁndings among cirrhotic patients with
NVUGIB.
Endoscopic ﬁnding Incidence (%)
Peptic ulcer 62 (60%)
Portal hypertensive gastropathy 15 (15%)
No lesion found 10 (10%)
Mucosal erosions 7 (7%)
Esophagitis 4 (4%)
Vascular ectasias 3 (3%)
Gastric polyps 2 (2%)
Table 4 Comparison of endoscopic ﬁndings among patients
with NVUGIB and compensated or decompensated cirrhosis.
Endoscopic ﬁnding Compensated
cirrhosis N= 52
Decompensated
cirrhosis N= 51
P
Peptic ulcer 28 (54%) 34 (67%) >0.1
PH. gastropathy* 7 (13%) 8 (16%) >0.5
No lesion found 8 (15%) 2 (4%) <0.05
Erosions 4 (8%) 3 (6%) >0.5
Esophagitis 3 (6%) 1 (2%) >0.1
Vascular ectasias 1 (2%) 2 (4%) >0.5
Gastric polyps 1 (2%) 1 (2%) >0.1
* Portal hypertensive gastropathy.
Peptic ulcer bleeding among patients with liver cirrhosis 145patients had conscious sedation. IV midazolam (2.5 mg) was
the agent used for conscious sedation. All endoscopies were
performed by two well-trained experienced endoscopists. In
patients with ulcers, stigmata of recent bleeding were recorded
according to the Forrest classiﬁcation.7 Active bleeding or
visible vessels were classiﬁed as high risk stigmata. Endoscopic
treatment (epinephrine injection and bipolar probe coagula-
tion) was performed only in these patients. Vigorous water irri-
gation was performed in all patients with adherent clot to
assess the presence of high risk stigmata. During hospitaliza-
tion patients were closely monitored for rebleeding and com-
plications until discharge. The end point was 2 weeks of
follow up or death. Outcomes were analyzed annually and
the reports transmitted to an independent experienced gastro-
enterologist with a particular interest in gastrointestinal bleed-
ing for comment and advice.
2.1. Patients and exclusions
During the study period 500 patients with concomitant acute
UGI bleeding and liver cirrhosis were admitted. One hundred
and forty-two patients (28%) did not undergo an inpatient
endoscopy for various reasons (Table 2). Three hundred and
ﬁfty-eight patients (72%) did undergo endoscopy of whom
255 (71%) had variceal bleeding and 103 (29%) NVUGIB.
Sixty-two patients (60%) with NVUGIB had PUB. Patients
who did not undergo endoscopy, had variceal bleeding and
NVUGIB other than PUB were excluded from the study. All
patients shown endoscopically to have PUB were included in
the analysis.
2.2. Data recording and statistics
A standardized data collection form was completed for each
patient. Recorded data included demographic information
and historical data: smoking history, drugs used like aspirin,
non-steroidal anti-inﬂammatory drugs and anticoagulants,
alcohol consumption, previous history of peptic ulcer, present-
ing symptoms and co-morbid illnesses. Physical and labora-
tory examination ﬁndings included hemodynamic data,
initial hemoglobin level, resuscitative efforts (blood transfu-
sion requirement), Child-Pugh status and Rockall score. The
endoscopic components of the database included the time
interval between presentation and endoscopy, identiﬁcationof the bleeding lesion, description of stigmata of bleeding
and method of endoscopic hemostasis if any. Outcomes
recorded included the frequency of rebleeding, surgical ther-
apy, complications and mortality. The cause of death and
the time interval (in hours) between endoscopy and death were
determined.
The data were registered, tabulated and analyzed
statistically using a program of SPSS version 15 to calculate
frequencies and the v2 test or Fisher’s exact test. A P value
<0.05 was considered to be signiﬁcant.
3. Results
Among 103 patients with NVUGIB, 62 patients (60%) had
PUB (Table 3). Peptic ulcer was the commonest cause of
NVUGIB in patients with compensated or decompensated cir-
rhosis (Table 4). A total of 62 patients having PUB were stud-
ied. Fifty percent were male and 50% female. Ages ranged
from 37 to 72 years, mean 59 ± 7 years. Thirty-three patients
(53%) agedP60 years. Seventeen patients (27%) had a history
of smoking. Thirty-nine patients (63%) were taking aspirin or
non-steroidal anti-inﬂammatory drugs and two (3%) anticoag-
ulants. Three patients (5%) were consuming alcohol. Ten pa-
tients (16%) had a previous history of peptic ulcer. Cirrhosis
was newly diagnosed during hospitalization for PUB in ten pa-
tients (16%) and had been previously diagnosed in 52 (84%).
The most common symptom on presentation was hema-
temesis in 33 patients (53%), melena in 15 (24%) and both
in 14 (23%). Thirty-two patients (52%) were hemodynamically
stable on admission and 30 (48%) were hemodynamically
instable. Twenty-eight (45%) patients had compensated cir-
rhosis and 34 (55%) decompensated cirrhosis. Six patients
(10%) had liver failure. Six patients (10%) had hepatocellular
Table 5 Co-morbidities other than cirrhosis among cirrhotic
patients with peptic ulcer bleeding.
Co-morbidity* Incidence (%)
Diabetes mellitus 31 (50%)
Ischemic heart disease ± arrhythmia 7 (11%)
Hypertension 6 (10%)
COPD** ± respiratory failure 3 (5%)
Cerebrovascular accident 5 (8%)
Asthma 2 (3%)
Heart failure 1 (2%)
Rheumatoid arthritis 1 (2%)
* Many patients had multiple co-morbidities.
** Chronic obstructive pulmonary disease.
146 A. Gado et al.carcinoma. Fifteen patients (24%) were Child-Pugh A, 16
(26%) B and 31 (50%) C. Co-morbid illnesses other than liver
cirrhosis were documented in 47 patients (76%) (Table 5). The
mean hemoglobin concentration was 9 ± 3 g/dl, 18 patients
(29%) had initial hemoglobin below 7 g/dl. Twenty-seven
patients (44%) required blood transfusion; the average num-
ber of units given was two.
All patients underwent emergency endoscopy during admis-
sion. The mean time from presentation to endoscopy was
29 ± 26 h (2–96 h). Endoscopy was conducted within 24 h of
presentation in 46 patients (74%). Forty patients (65%) bled
from gastric ulcers, 17 (27%) from duodenal ulcers and 5
(8%) from both. Thirty-one patients (50%) had ulcers with
clean base, 20 (32%) with pigmented spot and 11 (18%) with
adherent clot. Stigmata of portal hypertension (mosaic-like
pattern) during endoscopy were documented in 47 patients
(76%). Forty-seven patients (76%) had a Rockall score three
to ﬁve and 15 (24%) six to eight (Fig. 1). The mean full Rockall
score was ﬁve. Five patients (8%) rebled. Re-endoscopy was
performed in two patients (3%) due to rebleeding. Seven
patients (11%) developed complications during admission
(after endoscopy): liver failure in four patients (6%), deep
venous thrombosis in two (3%) and ascites in one (2%).
Fifty-seven patients (92%) were discharged. Five patients
(8%) died within the 2 weeks of their admission. The time
interval from endoscopy to death ranged from 8 to 220 h,
mean 78 ± 91 h. Death was due to continuous bleeding in
two patients (3%) and comorbid disease in three (5%). One
patient died from liver failure, one from pulmonary embolism
and one from cardiac arrest.
Mortality was 16% among male patients vs. 0.0% among
females (P= 0.02). Mortality was 3% among patients aged less0
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N
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Figure 1 Various Rockall scores in the 62 cirrhotic patients with
peptic ulcer bleeding.than 60 years vs. 12% aged 60 years or older (P= 0.211). Mor-
tality was 6% among patients with hematemesis vs. 13% with
melena vs. 7% with both (P= 0.685). Mortality was 6%
among patients who were hemodynamically stable on admis-
sion vs. 10% who were hemodynamically instable
(P= 0.588). Mortality was 4% in patients with compensated
cirrhosis vs. 12% in patients with decompensated cirrhosis
(P= 0.238). Mortality was 0% in patients with liver failure
vs. 9% in patients without liver failure (P= 0.445). Mortality
was 7% in patients with the Child-Pugh group A vs. 6% in pa-
tients with B vs. 10% with (P= 0.896). Mortality was 17%
among patients had initial hemoglobin below 7 g/dl. vs. 5%
who had initial hemoglobin 7 g/dl. or more (P= 0.112). Mor-
tality was 6% among patients with duodenal ulcers vs. 8% with
gastric ulcers vs. 20%with both (P= 0.581).Mortality was 0%
among patients who had ulcers with clean base vs. 10%with ﬂat
pigmented spot vs. 27% with adherent clot (P= 0.016). Mor-
tality was 60% in patients with rebleeding vs. 4% in patients
without rebleeding (P= 0.00001). Mortality was 29% in
patients with complications vs. 5% in patients without compli-
cations (P= 0.034). Mortality was 0.0% among patients who
had a low Rockall score (3–5) vs. 33% in those with a high score
(6–8) (P= 0.00003).4. Discussion
Patients with liver cirrhosis may present with gastrointestinal
bleeding caused by portal hypertension or by lesions found
in patients without cirrhosis. Gastrointestinal bleeding
accounts for up to 25% of all mortality in cirrhotic patients,
whether compensated or with severe liver disease, and both
may be associated with the development of life-threatening
complications.8 Excluding variceal bleeding, the most common
causes of UGI bleeding in cirrhotic patients are portal hyper-
tensive gastropathy and peptic ulcer disease.8 PUB accounts
for 30% of causes of gastrointestinal bleeding in patients with
cirrhosis, and for 50% of nonvariceal upper gastrointestinal
bleeding.9
PUB leads to substantial morbidity and mortality in
patients with liver cirrhosis.10 Physiopathology, treatment
and prognosis of PUB have never been described in cirrhotic
patients as opposed to variceal bleeding. Because cirrhosis is
generally an exclusion criterion in randomized controlled trials
concerning management of PUB, the efﬁcacy of standard of
care needs to be assessed in cirrhotic patients. Moreover, large
studies describing the prognosis of PUB treated according to
actual recommendations are lacking.10
In the current study we have assessed the prevalence and
outcome of PUB in patients with liver cirrhosis. PUB was
diagnosed in 17% of patients presenting with acute UGI bleed-
ing and liver cirrhosis and 60% of patients with NVUGIB.
Fifty percent of patients were males and 53% agedP60 years.
The most common symptom on presentation was hematemesis
(53%). Forty-eight percent were hemodynamically instable
on admission and 29% had initial hemoglobin below 7 g/dl.
Fifty-ﬁve percent had decompensated cirrhosis and 50% were
Child-Pugh C. Diabetes mellitus was documented in 50%.
Sixty-ﬁve percent of patients bled from gastric ulcers and
18% had ulcers with adherent clot. Twenty-four percent had
a Rockall score >5. Rebleeding occurred in 8% and complica-
tions in 11%. The overall mortality was 8%. Death was due to
Peptic ulcer bleeding among patients with liver cirrhosis 147continuous bleeding in 3% and comorbid disease in 5%. The
age, mode of presentation of the hemorrhage, hemodynamic
instability on arrival, severity of liver disease, initial hemoglo-
bin level or location of bleeding ulcer played no role in mortal-
ity. Male gender, endoscopic ﬁnding of adherent clot, bleeding
recurrence, development of complications during admission
and a Rockall score >5 were signiﬁcant factors for increasing
mortality (P= 0.02, 0.016, 0.00001, 0.034 and 0.00003
respectively).
Peptic ulcer was the second commonest cause of bleeding in
liver cirrhosis, following varices, and most frequent cause of
NVUGIB. Many patients had risk factors associated with pep-
tic ulcer disease. Twenty-seven percent were smokers, 63%
were using aspirin or non-steroidal anti-inﬂammatory drugs
and 5% were consuming alcohol. Sixteen percent had previous
history of peptic ulcer. Gastric biopsies were not examined for
Helicobacter pylori. In contrast to peptic ulcer disease in the
general population, the pathogenic role of Helicobacter pylori
in cirrhotic patients remains questionable and may not be a
major risk factor for peptic ulcer disease in cirrhotic
patients.8,11 it was reported that the role of Helicobacter pylori
infection seemed controversial in cirrhotic patients.10 The ben-
eﬁt of Helicobacter pylori eradication in patients with cirrhosis
and peptic ulcer disease has been questioned.11,12 Further-
more, eradication of Helicobacter pylori in patients with cir-
rhosis does not effectively reduce the recurrence of peptic
ulcers.10 The avoidance of peptic ulcer risk factors, and the
early diagnosis and treatment of peptic ulcer when present in
liver cirrhosis patients are important to prevent complications
(bleeding and mortality).
Co-morbid illnesses other than liver cirrhosis were docu-
mented in 76% of patients. Many patients had multiple co-
morbidities. Diabetes mellitus was the commonest co-morbid
disease (50%). It was reported that up to 96% of patients
with cirrhosis may be glucose intolerant and 30% may be
clinically diabetic.13 Currently, it is a matter for debate
whether type 2 diabetes mellitus in the absence of other risk
factors contributing to metabolic syndrome (obesity and
hypertriglyceridemia), could be a risk factor for the develop-
ment and progression of liver disease.14–16 On the other hand,
the diabetes which develops as a complication of cirrhosis is
known as ‘‘hepatogenous diabetes’’ and is not recognized
by the American Diabetes Association and the World Health
Organization as a speciﬁc independent entity.17 It was also re-
ported that the prevalence of diabetes was much higher in
hepatitis C virus-related cirrhosis and alcoholic liver disease,
but not in cholestatic liver disease suggesting the important
role of underlying cause in the development of diabetes in
these patients.18
Fifty percent of patients had ulcers with clean base, 32%
with pigmented spot and 18% with adherent clot. Endoscopic
ﬁnding of adherent clot was predictive of mortality of PUB.
No high risk bleeding stigmata were identiﬁed in any patient
with PUB. These may have been missed because endoscopy
was performed on the morning of the second day and not on
admission. During the study period, 9% of cirrhotic patients
admitted to our hospital with acute UGI bleeding died rapidly
after admission without having undergone an endoscopy due
to continued bleeding or rebleeding (for which reason they
were not included in the study). The mean time from admission
to death was 6 h (range 25 min–18 h). We intend in future toperform endoscopy as soon as patients have been resuscitated
and are stable.
Re-bleeding occurred in 8% of patients and 11% developed
complications during admission (mainly liver failure).
Rebleeding and complications were predictive of mortality of
PUB. It was reported that re-bleeding occurred in 7% of pa-
tients with PUB and liver cirrhosis.10 Maximum nonsurgical
treatment for PUB, including arterial embolization, should
always be applied to patients with cirrhosis.10 Recent data
indicate that most PUB-linked deaths are not direct sequelae
of the bleeding ulcer itself. Instead, mortality derives from
multi-organ failure or cardiopulmonary conditions suggesting
that improving treatments for the bleeding ulcer may
impact mortality by very little.20 Recognizing this possibility
is paramount for the implementation of strategies that provide
supportive care and prevent complications and key-organ
failure, as well as treat the ulcer.19
Mortality occurred in 8% of patients. Forty percent of the
deaths were directly related to the bleeding episode, whilst the
remaining deaths were associated with co-morbidities. Mortal-
ity is similar to that reported in PUB without liver cirrhosis.
Despite recent improvement in PUB management, mortality
of PUB remains high, ranging from 5% to 10%.20 Co-morbid-
ity is an important predictor of death in all patients with gastro
intestinal bleeding, in a recently published study of 10,428 pa-
tients with NVUGIB in non-cirrhotic patients, death was asso-
ciated with causes directly related to the bleeding episode in
only 29% of cases whilst in the remaining cases, co-morbidity
played a fundamental role.21
A high Rockall score was predictive of mortality of PUB.
The effectiveness of Rockall score as a predictor of in-hospital
death in cirrhotic patients with PUB proved to be similar to
that reported in non-cirrhotic patients.22 The Rockall scoring
system is a widely validated scoring system which was princi-
pally designed to predict death based on a combination of
clinical and endoscopic ﬁndings. Surprisingly, mortality was
not related to the severity of liver dysfunction as expressed
by clinical and laboratory criteria (Child-Pugh classiﬁcation).
The Child-Pugh classiﬁcation has an advantage over other
classiﬁcations in that all patients can be classiﬁed even when
some data are not (yet) available.8 However all classiﬁcation
systems have a margin of false positive and false negative pre-
diction.8 A score system based on one population may not be
applicable to others. The main purpose of a clinical classiﬁca-
tion system in this context is to provide a wider and more
objective approach to decision-making in the treatment of
these very difﬁcult patients.85. Summary
This study was performed in a community hospital in Egypt. It
showed that the commonest cause of NVUGIB in patients
with liver cirrhosis was PUB. PUB was associated with life-
threatening complications. Male gender, adherent clot, bleed-
ing recurrence, development of complications and a high
Rockall score were predictive of mortality of PUB. Many pa-
tients had a risk factor associated with peptic ulcer disease.
Avoiding risk factors, early diagnosis and treatment of peptic
ulcer in cirrhotic patients are important to prevent complica-
tions and must be emphasized to all physicians.
148 A. Gado et al.6. Conclusion
The commonest cause of NVUGIB in patients with liver cir-
rhosis was PUB. Mortality in patients with PUB was particu-
larly high among males, patients who had adherent clot,
bleeding recurrence, development of complications and a high
Rockall score.
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